The role of FDG-PET/CT in suspected recurrence of breast cancer

Cancer

Volumn 107, Issue 11, 2006, Pages 2545-2551

  Radan, Lea ^a   Ben Haim, Simona ^b   Bar Shalom, Rachel ^a,c   Guralnik, Luda ^a   Israel, Ora ^a,c  

^a Rambam Health Care Campus ^*  (Israel)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Breast cancer; Elevated tumor markers; PET CT; Recurrence

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FLUORODEOXYGLUCOSE; TAMOXIFEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; PATIENT REFERRAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TUMOR BIOPSY; TUMOR LOCALIZATION;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IODINE RADIOISOTOPES; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 33751576426     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22292     Document Type: Article

References (14)

1. Esserman L. Integration of imaging in the management of breast cancer. J Clin Oncol. 2005;23:1601-1602.
2. Buscombe JR, Holloway B, Roche N, Bombardieri E. Position of nuclear medicine modalities in the diagnostic work-up of breast cancer. Q J Nucl Med Mol Imaging. 2004;48:109-118.
3. Weir L, Worsley D, Bernstein V. The value of FDG positron emission tomography in the management of patients with breast cancer. Breast J. 2005;11:204-209.
4. Lind P, Igerc I, Beyer T, Reinprecht P, Hausegger K. Advantages and limitations of FDG PET in the follow-up of breast cancer. Eur J Nucl Med Mol Imaging. 2004;31 (Suppl 1):S125-S134.
5. Czernin J. FDG-PET in breast cancer: a different view of its clinical usefulness. Mol Imaging Biol. 2002;4:35-45.
6. Eubank WB, Mankoff DA. Evolving role of positron emission tomography in breast cancer imaging. Semin Nucl Med. 2005;35:84-99.
7. Suarez M, Perez-Castejon MJ, Jimenez A, et al. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers. Q J Nucl Med. 2002;46:113-121
8. Gallowitsch HJ, Kresnik E, Gasser J, et al. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging. Invest Radiol. 2003;38:250-256.
9. Tatsumi M, Cohade C, Mourtzikos KA, Fishman EK, Wahl RL. Initial experience with FDG-PET/CT in the evaluation of breast cancer. Eur J Nucl Med Mol Imaging. 2000;33:254-262.
10. Siggelkow W, Rath W, Buell U, Zimny M. FDG PET and tumour markers in the diagnosis of recurrent and metastatic breast cancer. Eur J Nucl Med Mol Imaging. 2004;31(Suppl 1):S118-124.
11. Zangheri B, Messa C, Picchio M, Gianolli L, Landoni C, Fazio F. PET/CT and breast cancer. Eur J Nucl Med Mol Imaging. 2004;31(Suppl 1):S135-S142.
12. Fueger BJ, Weber WA, Quon A, et al. Performance of 2-deoxy-2-[F-18] fluoro-D-glucose positron emission tomography and integrated PET/CT in restaged breast cancer patients. Mol Imaging Biol. 2005;7:369-376.
13. Eubank WB, Mankoff DA, Vesselle HJ, et al. Detection of locoregional and distant recurrences in breast cancer patients by using FDG PET. Radiographics. 2002;22:5-17.
14. Isasi CR, Moadel KM, Blaufox MD. A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Res Treat. 2005;90:105-112.